A recent article Jeanne Whallen at the Wall Street Journal highlights a line of thinking that many pharma companies, like AstroZeneca, are coming around to these days: we must be vigilant about ensuring that our drugs are promoted ethically.
Scott Bruns and Kathleen Meriwether of Ernst & Young count down the top five compliance risks facing life sciences companies, including sales & marketing risks, the FCPA and IFRS, as well as supply-chain integrity and aggregate spend.
September 3, 2010
September 2, 2010
September 1, 2010
August 31, 2010
September 2, 2010
July 19, 2010
July 16, 2010
June 24, 2010
August 24, 2010
July 19, 2010
June 29, 2010
May 9, 2010
September 2, 2010
September 3, 2010
September 2, 2010
September 1, 2010
August 31, 2010
August 30, 2010
September 3, 2010
September 2, 2010
September 2, 2010
August 31, 2010
August 19, 2010
September 3, 2010
September 3, 2010
February 1, 2010
The "Massive News" theme by: Press75.com
|
Home |
About |
Contact |
Authors |
Write for CCI |
Article Guildelines |
Compliance News |
People on the Move |
Legal Notice |
Privacy Policy |
Corporate Compliance Insights is a professionally designed and managed forum dedicated to online discussion and analysis of corporate compliance and governance topics. Additionally, Corporate Compliance Insights is a focused knowledge-sharing forum designed to educate and encourage informed interaction within the corporate compliance community.
